| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care
|
Rassy, E.
|
|
|
32 |
10 |
p. 1206-1208
|
article
|
| 2 |
A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning
|
van Ommen-Nijhof, A.
|
|
|
32 |
10 |
p. 1212-1215
|
article
|
| 3 |
Call for emergency action to limit global temperature increases, restore biodiversity, and protect health
|
Atwoli, L.
|
|
|
32 |
10 |
p. 1203-1205
|
article
|
| 4 |
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆
|
Cohen, R.
|
|
|
32 |
10 |
p. 1267-1275
|
article
|
| 5 |
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy ☆
|
Jerusalem, G.
|
|
|
32 |
10 |
p. 1256-1266
|
article
|
| 6 |
Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’
|
Emens, L.A.
|
|
|
32 |
10 |
p. 1308
|
article
|
| 7 |
Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’
|
Gutzmer, R.
|
|
|
32 |
10 |
p. 1310
|
article
|
| 8 |
Corrigendum to ‘P-195 Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients’
|
Nshizirungu, J.
|
|
|
32 |
10 |
p. 1309
|
article
|
| 9 |
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’
|
Slamon, D.J.
|
|
|
32 |
10 |
p. 1307
|
article
|
| 10 |
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|
Burstein, H.J.
|
|
|
32 |
10 |
p. 1216-1235
|
article
|
| 11 |
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
|
He, W.
|
|
|
32 |
10 |
p. 1286-1293
|
article
|
| 12 |
Editorial Board
|
|
|
|
32 |
10 |
p. iii
|
article
|
| 13 |
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
|
Miles, D.
|
|
|
32 |
10 |
p. 1245-1255
|
article
|
| 14 |
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
|
Palich, R.
|
|
|
32 |
10 |
p. 1294-1295
|
article
|
| 15 |
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
|
Hughes, B.G.M.
|
|
|
32 |
10 |
p. 1276-1285
|
article
|
| 16 |
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
|
Guisado-Vasco, P.
|
|
|
32 |
10 |
p. 1295-1297
|
article
|
| 17 |
Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061
|
Shitara, K.
|
|
|
32 |
10 |
p. 1303-1304
|
article
|
| 18 |
Severe COVID-19 in patients with hematological cancers presenting with viremia
|
Michot, J.M.
|
|
|
32 |
10 |
p. 1297-1300
|
article
|
| 19 |
Suboptimal nutritional support in cancer patients gets excellent results. Reply to the Letter to the Editor: ‘Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial’ by L. Bargetzi et al.
|
Bozzetti, F.
|
|
|
32 |
10 |
p. 1304-1305
|
article
|
| 20 |
Table of Contents
|
|
|
|
32 |
10 |
p. i-ii
|
article
|
| 21 |
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
|
Loi, S.
|
|
|
32 |
10 |
p. 1236-1244
|
article
|
| 22 |
Tumor deposits improve staging in colon cancer: what are the next steps?
|
Brouwer, N.P.M.
|
|
|
32 |
10 |
p. 1209-1211
|
article
|
| 23 |
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
|
Colombo, N.
|
|
|
32 |
10 |
p. 1300-1303
|
article
|
| 24 |
What is optimal nutritional support in acutely ill cancer patients? More may not be better
|
Bargetzi, L.
|
|
|
32 |
10 |
p. 1305-1306
|
article
|
Journal description